Improvement in the prognosis of Japanese breast cancer patients from 1946 to 2001 - An institutional review

Japanese Journal of Clinical Oncology

Volumn 34, Issue 8, 2004, Pages 457-462

  Yoshimoto, Masataka ^a   Tada, Keiichiro ^a   Hori, Haruko ^a   Morota, Akira ^a   Tanabe, Masahiko ^a   Nishimura, Seiichiro ^a   Takahashi, Kaoru ^a   Makita, Masujiro ^a   Iwase, Takuji ^a   Kasumi, Fujio ^a   Takahashi, Syunji ^a   Ito, Yoshinori ^a   Oguchi, Masahiro ^a   Yamashita, Takashi ^a   Akiyama, Futoshi ^a   Sakamoto, Goi ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Breast cancer; Chronological change; Japanese; Survival

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GONADORELIN AGONIST; MELPHALAN; MITOMYCIN C; PACLITAXEL; TAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

AGE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOMA IN SITU; CHRONOLOGY; CLINICAL FEATURE; FEMALE; FREQUENCY ANALYSIS; HISTOPATHOLOGY; HISTORY OF MEDICINE; HUMAN; JAPAN; LYMPH NODE METASTASIS; MASTECTOMY; ORGAN PRESERVATION; POSTMENOPAUSE; POSTOPERATIVE CARE; PROGNOSIS; SURGICAL TECHNIQUE; ADULT; AGED; BREAST TUMOR; CANCER STAGING; CLINICAL TRIAL; LYMPHADENECTOMY; MENOPAUSE; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; STATISTICS; SURVIVAL RATE; TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; JAPAN; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MASTECTOMY; MENOPAUSE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TIME FACTORS;

EID: 7944239501     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyh076     Document Type: Article

References (9)

1. Cancer Statistics in Japan - 2001. Foundation for Promotion of Cancer Research.
2. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 2000;355:1822.
3. Miller AB. Why is breast-cancer mortality declining? Lancet Oncol 2003;4:251-4.
4. Otto SJ, Fracheboud J, Looman CW, Broeders MJ, Boer R, Hendriks JH, et al. Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: A systemic review. Lancet 2003;361:1411-7.
5. Tabar L, Yen MF, Vitak B, Chen HH, Smith RA, Duffy SW. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 2002;361:1405-10.
6. Andersen LD, Remington P, Trentham-Dietz A, Reeves M. Assessing a decade of progress in cancer control. Oncologist 2002;7:200-4.
7. General Rules for Clinical and Pathological Recording of Breast Cancer. September 2000 (The 14th Edition), The Japanese Breast Cancer Society.
8. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 1998;351:1451-67.
9. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet 1998;352:930-42.